Execs at this year's J.P. Morgan Healthcare Conference agreed the tone was somewhere between gloom and sunshine.
The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.
Yes, next year may be a "a year of uncertainty," PwC says. But it's also a year of "opportunity" for pharma.
Blockbuster drug launches have strained health systems budgets in recent years by driving sizable spending hikes. But that trend may be nearing a lull, a new PwC report says.